Neisseria meningitidis capsular polysaccharide-specific B-cell receptor (Nm-CPS BCR)

Neisseria meningitidis capsular polysaccharide-specific B-cell receptors (BCRs) are the primary immunological sensors for identifying the protective carbohydrate coating of meningococci (Stephens et al., 2007, PMID: 17597300). These receptors are essential for the generation of protective antibodies that neutralize the bacteria during invasive infections such as meningitis and septicemia (WHO, 2023). The capsular polysaccharides are chemically distinct for each serogroup (A, B, C, W, Y, and X), and the BCRs must exhibit high specificity to provide effective immunity (CDC, 2023). Therapeutic intervention primarily involves the use of conjugate vaccines, which link these polysaccharides to carrier proteins to enhance BCR activation and induce long-term memory (Pollard et al., 2009, PMID: 19855371). Once activated, the resulting antibodies facilitate the destruction of the pathogen through the classical complement pathway and opsonophagocytosis. A significant challenge in targeting these receptors involves Serogroup B, where the capsule mimics human neural antigens, requiring specialized vaccine strategies to ensure safety and efficacy (Finne et al., 1983, PMID: 6353212).

Other names

Anti-meningococcal antibodiesMeningococcal capsular polysaccharide antibodiesB-cell receptors for Neisseria meningitidis capsular polysaccharidesMeningococcal polysaccharide-specific immunoglobulin

Vaccines act as antigens that bind to and cross-link B-cell receptors, stimulating clonal expansion and differentiation into plasma cells (Pollard et al., 2009, PMID: 19855371). These plasma cells secrete high-affinity antibodies that bind to the bacterial capsule, triggering the classical complement pathway for bacteriolysis or facilitating opsonophagocytosis by host immune cells (Stephens et al., 2007, PMID: 17597300).